Updated: Oct 20
Medically reviewed by ChinaCureLink Team
Table of Content
Introduction
Patients researching solid tumors may encounter autologous NK cell therapy as an adjunct to cancer immunotherapy. In China, this treatment is available through the Boao Lecheng International Medical Tourism Pilot Zone's “pilot implementation and special access” pathway. This guide explains what the treatment is, who may be considered, its estimated cost, where it is offered, and what international patients should know before pursuing it.
Key Takeaways |
|
What Is Autologous NK Cell Therapy?
Autologous NK cell therapy uses natural killer (NK) cells collected from the patient's own peripheral blood. The cells are cultured, expanded, and activated outside the body before being administered back to the patient.
In solid-tumor NK cell therapy in China, autologous NK cells may be combined with immunotherapeutic agents. This strategy is intended to leverage the complementary effects of innate immune cells and immunotherapy while addressing the immunosuppressive tumor microenvironment.
The treatment is positioned as an auxiliary approach alongside existing anticancer treatments. It is not a replacement for standard cancer treatment, and treatment information explicitly states that it cannot completely cure tumors or guarantee efficacy.
Is Autologous NK Cell Therapy Available in China?
Yes. The treatment is included in the official conversion application directory under the Boao Lecheng International Medical Tourism Pilot Zone's “pilot implementation and special access” policy.
The regulatory classification is low risk, with a registration year of 2025. This status provides a specific access pathway within the designated pilot zone; it does not mean that the treatment has nationwide approval for use throughout China.
Availability also depends on physician assessment and the patient's individual medical circumstances. International patients considering the treatment should establish their eligibility with the treating medical team before making travel arrangements
Where Is the Treatment Offered for Solid Tumor NK Cell therapy China?
The treatment is offered at Hainan Haikong Le City Hospital (West China Le City Hospital of Sichuan University) in Hainan.
Technical support is provided by Hainan Gan Jing Biotechnology Co., Ltd. The cell product uses autologous NK cells obtained from the patient's own peripheral blood and processed through in-vitro culture, expansion, and activation.
Who May Be Eligible?
Eligibility applies to patients with the listed solid tumor types. Suitability is evaluated according to the patient's pathological tumor type, disease stage, and previous treatments.
The attending physician determines suitability through a face-to-face medical evaluation. The treatment information does not establish eligibility for an individual patient based solely on diagnosis.
Final eligibility is determined by the treating medical team after a face-to-face consultation and review of the patient's medical records.
How Much Does It Cost?
The estimated cost is ¥49,800 (approximately US$6,900) per shot. A treatment cycle consists of 3 to 6 shots, administered once every 2 weeks. This means the treatment-session cost across a full cycle would be approximately ¥149,400–¥298,800, or about US$20,700–US$41,400, before any separately charged services.
The USD figures use an approximate exchange rate of ¥7.2 per US$1 and are provided as a reference.
The stated treatment price does not necessarily include consultation, diagnostic testing, hospitalization, translation or coordination services, or travel. Confirm final pricing and the full scope of charges directly with the hospital.
Why International Patients May Consider This Option
For some international patients, access to an adjunctive immunotherapy pathway that is not routinely available in their home country may be worth discussing with a qualified specialist. The Boao Lecheng pathway provides a supervised route for eligible patients to explore this treatment within a designated medical-access zone.
The treatment is intended to supplement existing anticancer care rather than replace it. Patients should therefore discuss the potential role of NK cell therapy, its risks and uncertainties, and available alternatives directly with their oncology team.
How ChinaCureLink Can Help Patients Access This Treatment
We help international patients explore available treatment options and facilitate communication with appropriate medical specialists. Patients should discuss potential benefits, risks, eligibility, and alternatives directly with qualified physicians. ChinaCureLink does not represent or endorse the treatment technology, manufacturer, or hospital.
Case review: We collect relevant medical history and solid tumor-management records to help determine whether a case is appropriate for physician review.
Hospital coordination: We help connect patients with the treating team at Hainan Haikong Le City Hospital (West China Le City Hospital of Sichuan University) in China for an initial assessment.
Online consultation before travel: Patients can discuss potential eligibility, the procedure, and expected next steps with the medical team remotely before committing to international travel.
Coordination support: Depending on the case, this can include translation assistance, appointment scheduling, and logistics coordination.
Considering This Treatment in China?
Before planning travel, speak with a qualified specialist to determine whether the treatment is appropriate for your condition and whether you meet the medical eligibility requirements. ChinaCureLink can help international patients arrange a specialist review and explore the treatment pathway in China. [Request a Medical Review / Speak With a Specialist]
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
★★★★☆ Pongsakorn · Thailand · Feb 2025 · Verified “Kiki at Medebound is amazing — so professional and helpful! They got my video consultation with an MD Anderson expert set up super fast, within just 5 working days. I am so grateful for their support.” |
Frequently Asked Questions
Is autologous NK cell therapy available in China?
Yes. It is available through the Boao Lecheng International Medical Tourism Pilot Zone's “pilot implementation and special access” pathway at Hainan Haikong Le City Hospital. This is a designated pilot-zone access pathway, not nationwide approval.
How much does autologous NK cell therapy cost in China?
The estimated cost is ¥49,800 (approximately US$6,900) per shot. A treatment cycle consists of 3–6 shots given once every 2 weeks, making the treatment component approximately US$20,700–US$41,400 per cycle.
Who may qualify for autologous NK cell therapy?
Patients with the listed solid tumor types may be considered. Suitability is evaluated based on pathological type, stage, and previous treatments through a face-to-face assessment by the attending physician.
Is NK cell therapy a replacement for cancer treatment?
No. This treatment is positioned as an adjunct or supplement to existing anticancer treatment. It cannot completely cure tumors, and efficacy is not guaranteed.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
